“At the moment, there are no reliable biomarkers or screening tools that can detect pancreatic cancer early,” said Bo Yuan, a PhD candidate at Harvard University, who presented the study. “The purpose of this study was to develop an artificial intelligence tool that can help clinicians identify people at high risk for pancreatic cancer so they can be enrolled in prevention or surveillance programs and hopefully benefit from early treatment.” Read more . . .
An artificial intelligence (AI) model trained using sequential health information derived from electronic health records identified a subset of individuals with a 25-fold risk of developing pancreatic cancer within three to 36 months, according to results presented at the AACR Annual Meeting 2022, held April 8-13.